Compare Stocks → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXOTCMKTS:APLIFNASDAQ:LIXTNASDAQ:PRFXNASDAQ:TRVI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.18+0.9%$1.87$1.08▼$5.50$9.35M0.9618,205 shs13,919 shsAPLIFAppili Therapeutics$0.03$0.02$0.02▼$0.08$3.04M-0.3451,219 shs3,100 shsLIXTLixte Biotechnology$3.30-1.5%$2.81$1.58▼$9.50$7.43M-0.28456,944 shs524 shsPRFXPainReform$0.85-0.2%$1.76$0.69▼$26.41$1.72M0.53119,249 shs6,240 shsTRVITrevi Therapeutics$2.95+0.3%$2.97$0.97▼$4.00$203.43M0.86280,255 shs228 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+1.18%-1.67%-34.81%-55.64%-73.41%APLIFAppili Therapeutics+10.76%+10.32%+16.81%+25.23%+2.96%LIXTLixte Biotechnology-4.47%+0.30%+50.42%+53.95%-49.70%PRFXPainReform+0.10%-10.40%-50.62%-57.54%-85.59%TRVITrevi Therapeutics+3.70%+4.63%-18.11%+117.78%-1.34%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics2.4174 of 5 stars3.54.00.00.01.33.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/ATRVITrevi Therapeutics3.00Buy$8.50188.14% UpsideCurrent Analyst RatingsLatest LIXT, PRFX, TRVI, APLIF, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AAPLIFAppili Therapeutics$280K12.04N/AN/A($0.05) per share-0.56LIXTLixte BiotechnologyN/AN/AN/AN/A$0.22 per shareN/APRFXPainReformN/AN/AN/AN/A$4.65 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)APLIFAppili Therapeutics-$6.99M-$0.04N/AN/AN/A-456.86%N/A-229.96%6/21/2024 (Estimated)LIXTLixte Biotechnology-$5.09M-$2.70N/A∞N/AN/A-1,202.60%-119.91%5/8/2024 (Estimated)PRFXPainReform-$9.34MN/A0.00∞N/AN/AN/AN/A5/20/2024 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)Latest LIXT, PRFX, TRVI, APLIF, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/A3/19/2024Q4 2023LIXTLixte BiotechnologyN/A-$0.41-$0.41-$0.41N/AN/A2/13/2024Q3 2024APLIFAppili Therapeutics-$0.01-$0.01N/AN/AN/A$0.36 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95APLIFAppili TherapeuticsN/A0.460.46LIXTLixte BiotechnologyN/A13.7213.72PRFXPainReformN/A4.074.07TRVITrevi TherapeuticsN/A15.0315.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%APLIFAppili TherapeuticsN/ALIXTLixte Biotechnology5.10%PRFXPainReform37.28%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%APLIFAppili Therapeutics11.84%LIXTLixte Biotechnology15.50%PRFXPainReform34.40%TRVITrevi Therapeutics27.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics157.92 million3.03 millionNot OptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableLIXTLixte Biotechnology32.25 million1.90 millionNot OptionablePRFXPainReform72.03 million1.33 millionNot OptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableLIXT, PRFX, TRVI, APLIF, and AKTX HeadlinesSourceHeadlineCritical Analysis: Pliant Therapeutics (NASDAQ:PLRX) vs. Trevi Therapeutics (NASDAQ:TRVI)americanbankingnews.com - April 20 at 2:16 AMTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.com - April 18 at 10:56 AMTwo stand-ups to perform at Trevi this Saturdaysaultstar.com - April 17 at 7:02 PMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferencefinance.yahoo.com - April 9 at 9:54 AMTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferenceprnewswire.com - April 9 at 7:30 AMTrevi Therapeutics appoints new VP for clinical developmentuk.investing.com - April 4 at 7:56 PMWhy Trevi Therapeutics (TRVI) Stock Might be a Great Pickzacks.com - April 4 at 9:31 AMTrevi Therapeutics to Participate in Upcoming April Eventsprnewswire.com - April 4 at 7:30 AMTrevi piles into Melbourne’s Link megaproject with four hyrdromillsglobalconstructionreview.com - April 3 at 10:24 AMCity worker cleans coins at Trevi Fountain in Romechinaview.cn - April 2 at 8:36 PMTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Teamfinance.yahoo.com - April 2 at 10:35 AMTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itmsn.com - March 29 at 7:12 PMTrevi Italian Restaurant at Forum Shops unexpectedly closesmsn.com - March 28 at 9:44 PMProminent Trevi Italian Restaurant Abruptly Closes at the Forum Shopsmsn.com - March 27 at 1:26 PMTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 21 at 11:14 AMTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 21 at 7:22 AMTrevi Therapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 9:21 PMTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023msn.com - March 20 at 9:21 PMTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trialsfinance.yahoo.com - March 20 at 9:21 PMGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossamsn.com - March 17 at 10:44 PMGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossamsn.com - March 16 at 4:38 PMWhat happens to the coins tossed into Rome's Trevi Fountain?astroawani.com - March 15 at 11:04 PMTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024finance.yahoo.com - March 13 at 8:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Appili TherapeuticsOTCMKTS:APLIFAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.Lixte BiotechnologyNASDAQ:LIXTLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.PainReformNASDAQ:PRFXPainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.